Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Keros Therapeutics, Inc. Director's Dealing 2021

Nov 4, 2021

32602_dirs_2021-11-03_999e427f-1c5a-4bb6-9587-92f6fef359f5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-11-01

Reporting Person: Knowles Julius (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-11-01 Common Stock S 7057 $41.85 Disposed 421041 Indirect
2021-11-01 Common Stock S 4599 $41.85 Disposed 284557 Indirect
2021-11-01 Common Stock S 7350 $42.43 Disposed 413691 Indirect
2021-11-01 Common Stock S 4797 $42.43 Disposed 279760 Indirect
2021-11-02 Common Stock S 3252 $42.10 Disposed 410439 Indirect
2021-11-02 Common Stock S 2120 $42.10 Disposed 277640 Indirect
2021-11-02 Common Stock S 1518 $43.04 Disposed 408921 Indirect
2021-11-02 Common Stock S 991 $43.04 Disposed 276649 Indirect
2021-11-03 Common Stock S 6067 $41.65 Disposed 402854 Indirect
2021-11-03 Common Stock S 3957 $41.65 Disposed 272692 Indirect
2021-11-03 Common Stock S 3597 $42.45 Disposed 399257 Indirect
2021-11-03 Common Stock S 2346 $42.45 Disposed 270346 Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9).

F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive.